Intra-Cellular Therapies Inc.

NAS: ITCI

GO
/marketstate/country/us

Market open

 --Real time quotes

Aug 19, 2022, 10:49 a.m.

/zigman2/quotes/209441868/composite

$

51.51

Change

+0.77 +1.51%

Volume

Volume 243,721

Real time quotes

/zigman2/quotes/209441868/composite

Previous close

$ 50.74

$ 51.51

Change

+0.77 +1.51%

Day low

Day high

$49.75

$51.55

Open

52 week low

52 week high

$28.45

$66.00

Open

Annual Financials for Intra-Cellular Therapies Inc.

Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue 245,837-60,61322.81M83.8M
Cost of Goods Sold (COGS) incl. D&A -368,673477,1211.9M8.03M
COGS excluding D&A ---1.37M7.5M
Depreciation & Amortization Expense 213,872368,673477,121528,118533,360
Depreciation 213,872368,673477,121528,118533,360
Amortization of Intangibles -----
Gross Income -(368,673)(416,508)20.92M75.77M
20172018201920202021 5-year trend
SG&A Expense 102.87M161.9M153.6M252.15M361.46M
Research & Development 79.42M132.17M89.12M65.78M88.85M
Other SG&A 23.45M29.73M64.47M186.36M-
Other Operating Expense -----
Unusual Expense -----
EBIT after Unusual Expense -----
Non Operating Income/Expense -----
Non-Operating Interest Income 4.01M7.14M6.29M4.24M1.57M
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (98.83M)(155.13M)(147.72M)(226.99M)(284.12M)
Income Tax (1.06M)1,6001,60013,5135,631
Income Tax - Current Domestic (14.77M)5.06M8.49M40.06M53.08M
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic 13.71M(5.05M)(8.48M)(40.05M)(53.07M)
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (97.77M)(155.13M)(147.72M)(227.01M)(284.13M)
Minority Interest Expense -----
Net Income (97.77M)(155.13M)(147.72M)(227.01M)(284.13M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (97.77M)(155.13M)(147.72M)(227.01M)(284.13M)
Preferred Dividends -----
Net Income Available to Common (97.77M)(155.13M)(147.72M)(227.01M)(284.13M)
EPS (Basic) (2.12)(2.84)(2.68)(3.23)(3.50)
Basic Shares Outstanding 46.18M54.71M55.19M70.36M81.25M
EPS (Diluted) (2.12)(2.84)(2.68)(3.23)(3.50)
Diluted Shares Outstanding 46.18M54.71M55.19M70.36M81.25M
EBITDA (102.63M)(161.9M)(153.53M)(230.7M)(285.15M)
Link to MarketWatch's Slice.